This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

Christopher Ray Aker net worth and biography

Christopher Aker Biography and Net Worth

VP of Regulus Therapeutics

Mr. Aker joined Regulus in February 2011 and currently serves as Senior Vice President and General Counsel. Prior to joining Regulus, Mr. Aker served as the Senior Director, Administration and Senior Corporate Counsel for Phenomix Corporation, a privately-held biopharmaceutical company, and was responsible for operational and legal oversight. Prior to Phenomix, Mr. Aker was Senior Corporate Counsel at SUGEN, Inc., a wholly-owned subsidiary of Pharmacia, until its acquisition by Pfizer. Prior to SUGEN, Mr. Aker was in private practice with various law firms. Mr. Aker received his Bachelor of Arts degree in International Relations from the University of California, Davis and his J.D. from the Santa Clara University.

What is Christopher Ray Aker's net worth?: The estimated net worth of Christopher Ray Aker is at least $58,038.06 as of May 17th, 2021. Mr. Aker owns 41,754 shares of Regulus Therapeutics stock worth more than $58,038 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Aker may own. Additionally, Mr. Aker receives an annual salary of $575,940.00 as VP at Regulus Therapeutics. Learn More about Christopher Ray Aker's net worth.
How old is Christopher Ray Aker?: Mr. Aker is currently 63 years old. There are 4 older executives and no younger executives at Regulus Therapeutics. Learn More on Christopher Ray Aker's age.
What is Christopher Ray Aker's salary?: As the VP of Regulus Therapeutics Inc., Mr. Aker earns $575,940.00 per year. There are 2 executives that earn more than Mr. Aker. The highest earning executive at Regulus Therapeutics is Mr. Joseph P. Hagan M.B.A., CEO & Director, who commands a salary of $958,230.00 per year. Learn More on Christopher Ray Aker's salary.
How do I contact Christopher Ray Aker?: The corporate mailing address for Mr. Aker and other Regulus Therapeutics executives is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. Regulus Therapeutics can also be reached via phone at (858) 202-6300 and via email at [email protected]. Learn More on Christopher Ray Aker's contact information.
Has Christopher Ray Aker been buying or selling shares of Regulus Therapeutics?: Christopher Ray Aker has not been actively trading shares of Regulus Therapeutics during the past quarter. Most recently, Christopher Ray Aker sold 860 shares of the business's stock in a transaction on Monday, May 17th. The shares were sold at an average price of $0.89, for a transaction totalling $765.40. Following the completion of the sale, the vice president now directly owns 41,754 shares of the company's stock, valued at $37,161.06. Learn More on Christopher Ray Aker's trading history.
Who are Regulus Therapeutics' active insiders?: Regulus Therapeutics' insider roster includes Christopher Aker (VP), Denis Drygin (Insider), and Joseph Hagan (CEO). Learn More on Regulus Therapeutics' active insiders.
Are insiders buying or selling shares of Regulus Therapeutics?: During the last twelve months, Regulus Therapeutics insiders bought shares 1 times. They purchased a total of 4,000 shares worth more than $7,280.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 2 times. They sold a total of 20,048 shares worth more than $23,857.12. The most recent insider tranaction occured on July, 25th when Director Kathryn J Collier bought 4,000 shares worth more than $7,280.00. Insiders at Regulus Therapeutics own 4.4% of the company. Learn More about insider trades at Regulus Therapeutics.
Information on this page was last updated on 7/25/2024.

Christopher Ray Aker Insider Trading History at Regulus Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/17/2021	Sell	860	$0.89	$765.40	41,754
2/16/2021	Sell	828	$1.72	$1,424.16	42,614
8/14/2020	Sell	872	$0.61	$531.92	26,638
5/15/2020	Sell	909	$0.63	$572.67	27,510
2/18/2020	Sell	888	$0.83	$737.04	28,419
1/2/2020	Sell	2,239	$0.97	$2,171.83	29,307
11/14/2019	Sell	833	$0.64	$533.12	31,546
10/1/2019	Sell	2,346	$0.68	$1,595.28	32,379
8/15/2019	Sell	899	$0.55	$494.45
7/1/2019	Sell	2,225	$1.31	$2,914.75	35,624
5/15/2019	Sell	6,950	$1.41	$9,799.50	66,259
4/1/2019	Sell	2,710	$0.98	$2,655.80	6,287

Christopher Ray Aker Buying and Selling Activity at Regulus Therapeutics

Regulus Therapeutics Company Overview

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Today's Range

Now: $1.40

$1.30

$1.41

50 Day Range

MA: $1.54

$1.40

$1.82

2 Week Range

Now: $1.40

$1.08

$3.79

Volume

139,535 shs

Average Volume

1,231,952 shs

Market Capitalization

$91.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63

Missed Nvidia? Watch this ASAP

From Brownstone Research | Ad

Click here and I’ll tell you everything you need to know.

Christopher Aker Biography and Net Worth

What is Christopher Ray Aker's net worth?

How old is Christopher Ray Aker?

What is Christopher Ray Aker's salary?

How do I contact Christopher Ray Aker?

Has Christopher Ray Aker been buying or selling shares of Regulus Therapeutics?

Who are Regulus Therapeutics' active insiders?

Are insiders buying or selling shares of Regulus Therapeutics?